Literature DB >> 3876221

Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.

J Stenderup, J Eriksen, S B Pedersen, L V Christiansen.   

Abstract

Six patients with alcoholic cirrhosis of the liver received 100 mg tolfenamic acid p.o. and i.v. The disposition of tolfenamic acid could be described by a two-compartment open body model, with a mean central compartment volume of 8.71, and a beta-phase volume of 25 l. The elimination rate constant ke averaged 1.13 h-1 and the half-life of the beta-phase was 1.73 h; the mean total plasma clearance was 159 ml/min. These pharmacokinetic parameters differed only slightly from those in two groups of healthy volunteers studied previously; ke was significantly reduced by about 30% in the patients but none of the other parameters differed significantly. There was good correlation between individual elimination rate constants or plasma clearances with the liver function tests, serum albumin and P-coagulation factors. Oral absorption was good and bioavailability of about 100% was shown by comparison of the areas under the plasma concentration - time curves after i.v. and p.o. administration. Metabolism was qualitatively and quantitatively very similar to previous observations in healthy volunteers. There seems no reason to reduce the dose of tolfenamic acid in patients with compensated alcoholic cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3876221     DOI: 10.1007/bf00544069

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Assay of tolfenamic acid and its metabolites by liquid chromatography on dynamically modified silica: application in pharmacokinetics.

Authors:  S H Hansen; S B Pedersen
Journal:  J Pharm Biomed Anal       Date:  1986       Impact factor: 3.935

2.  Osteoarthritis of the knee treated with tolfenamic acid.

Authors:  E Zachariae; J Sylvest
Journal:  Scand J Rheumatol       Date:  1972       Impact factor: 3.641

3.  Long-term therapy with tolfenamic acid pINN. A clinical and toxicological study with special reference to clinical and chemical laboratory parameters.

Authors:  K Sørensen; L V Christiansen
Journal:  Scand J Rheumatol Suppl       Date:  1977

Review 4.  Effects of liver disease on drug disposition in man.

Authors:  G R Wilkinson; S Schenker
Journal:  Biochem Pharmacol       Date:  1976-12-15       Impact factor: 5.858

5.  Inhibition of prostaglandin biosynthesis by tolfenamic acid in vitro.

Authors:  I B Lindén; J Parantainen; H Vapaatalo
Journal:  Scand J Rheumatol       Date:  1976       Impact factor: 3.641

6.  A comparative, double-blind study on tolfenamic acid in the treatment of rheumatoid arthritis.

Authors:  V Rejholec; H Vapaatalo; O Tokola; G Gothoni
Journal:  Scand J Rheumatol Suppl       Date:  1979

7.  Tolfenamic acid. Detection and structure of urinary metabolites.

Authors:  S B Pedersen; B Alhede; O Buchardt; J Møller; K Bock
Journal:  Arzneimittelforschung       Date:  1981

8.  Human metabolism of tolfenamic acid. II. Structure of metabolites and C-13 NMR assignments of fenamates.

Authors:  R G Khalifah; C E Hignite; P J Pentikäinen; A Penttilä; P J Neuvonen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

9.  Prophylactic treatment of migraine with tolfenamic acid. A comparative double-blind crossover study between tolfenamic acid and placebo.

Authors:  B M Mikkelsen; J V Falk
Journal:  Acta Neurol Scand       Date:  1982-07       Impact factor: 3.209

10.  Pharmacokinetics of tolfenamic acid: disposition in bile, blood and urine after intravenous administration to man.

Authors:  P J Pentikäinen; O Tokola; E Alhava; A Penttilä
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.